REFERENCES

1. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.

2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97.

3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22.

4. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107.

5. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40.

6. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353-64.

7. Barnhart JW, Sefranka JA, McIntosh DD. Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). Am J Clin Nutr. 1970;23:1229-33.

8. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994;74:875-83.

9. Yamashita S, Masuda D, Harada-Shiba M, et al. Effectiveness and safety of lipid-lowering drug treatments in japanese patients with familial hypercholesterolemia: familial hypercholesterolemia expert forum (FAME) study. J Atheroscler Thromb. 2022;29:608-38.

10. Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19:1325-32.

11. Hirano K, Ikegami C, Tsujii K, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005;25:2422-7.

12. Yamashita S, Masuda D, Matsuzawa Y. Did we abandon probucol too soon? Curr Opin Lipidol. 2015;26:304-16.

13. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207:16-23.

14. Matsuzawa Y, Yamashita S, Kameda K, Kubo M, Tarui S, Hara I. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. Atherosclerosis. 1984;53:207-12.

15. Giammanco A, Noto D, Barbagallo CM, et al. Hyperalphalipoproteinemia and beyond: the role of HDL in cardiovascular diseases. Life. 2021;11:581.

16. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-9.

17. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917-23.

18. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-80.

19. Robins SJ, Lyass A, Brocia RW, Massaro JM, Vasan RS. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis. 2013;228:230-6.

20. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010;121:366-74.

21. Miller NE. CETP inhibitors and cardiovascular disease: time to think again. F1000Res. 2014;3:124.

22. Lee DM, Alaupovic P, Knight-Gibson C, Bagdade JD. Apolipoprotein-B subclasses as acceptors of cholesteryl esters transferred by CETP. Eur J Clin Invest. 2008;38:734-42.

23. Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024;274:32-45.

24. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478-86.

25. Hirata A, Okamura T, Sugiyama D, et al. The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of japanese general population. J Atheroscler Thromb. 2016;23:800-9.

26. Hirata A, Sugiyama D, Watanabe M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: the EPOCH-JAPAN study. J Clin Lipidol. 2018;12:674-84.e5.

27. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22.

28. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-30.

29. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99.

30. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933-42.

31. Ferri N, Corsini A, Sirtori CR, Ruscica M. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res. 2018;128:29-41.

32. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-73.

33. Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217-27.

34. Krishna R, Gheyas F, Liu Y, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther. 2017;102:832-40.

35. Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR. Cholesteryl ester transfer protein: an enigmatic pharmacology - Antagonists and agonists. Atherosclerosis. 2018;278:286-98.

36. Buckley MM, Goa KL, Price AH, Brogden RN. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989;37:761-800.

37. Tawara K, Tomikawa M, Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol. 1986;40:123-33.

38. Naruszewicz M, Carew TE, Pittman RC, et al. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res. 1984;25:1206-13.

39. Baker SG, Joffe BI, Mendelsohn D, et al. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982;62:7-11.

40. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol. 1988;62:66B-72B.

41. Durrington PN, Miller JP. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. Atherosclerosis. 1985;55:187-94.

42. Sanjurjo P, Martul P, Sasieta M, Lafuente P, Ariza F, Cabeza I. Treatment with probucol of children with familial hypercholesterolaemia. Acta Paediatr Scand. 1988;77:132-5.

43. Quach D, Vitali C, La FM, et al. Cell lipid metabolism modulators 2-bromopalmitate, D609, monensin, U18666A and probucol shift discoidal HDL formation to the smaller-sized particles: implications for the mechanism of HDL assembly. Biochim Biophys Acta. 2016;1861:1968-79.

44. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-64.

45. Bagdade JD, Ritter MC, Subbaiah PV. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest. 1991;87:1259-65.

46. Bagdade JD, Kaufman D, Ritter MC, Subbaiah PV. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. Atherosclerosis. 1990;84:145-54.

47. Cao J, Xu Y, Li F, Shang L, Fan D, Yu H. Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice. J Transl Med. 2018;16:155.

48. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb. 1991;11:476-81.

49. Chiesa G, Michelagnoli S, Cassinotti M, et al. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism. 1993;42:229-35.

50. Ishigami M, Yamashita S, Sakai N, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997;27:285-92.

51. Adlouni A, El Messal M, Saïle R, Parra H, Fruchart J, Ghalim N. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. Atherosclerosis. 2000;152:433-40.

52. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986;57:29H-35H.

53. Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol. 1996;23:598-602.

54. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis. 2008;200:329-35.

55. Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol. 2004;24:2345-50.

56. Yakushiji E, Ayaori M, Nishida T, et al. Probucol-oxidized products, spiroquinone and diphenoquinone, promote reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2016;36:591-7.

57. Hafiane A, Pisaturo A, Ronca A, Incerti M, Kiss RS, Favari E. Probucol treatment is associated with an ABCA1-independent mechanism of cholesterol efflux to lipid poor apolipoproteins from foam cell macrophages. BBA Adv. 2021;1:100003.

58. Hafiane A, Ronca A, Kiss RS, Favari E. High density lipoprotein-based therapeutics: novel mechanism of probucol in foam cells. Front Cardiovasc Med. 2022;9:895031.

59. Hoekstra M, Van Eck M. Probucol-induced hypocholesterolemia is not associated with exacerbated foam cell formation in ABCG1 knockout mice. Atherosclerosis. 2020;296:91-2.

60. Miida T, Yamaguchi T, Tsuda T, Okada M. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis. 1998;138:129-34.

61. Hong SC, Zhao SP, Wu ZH. Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits. Int J Cardiol. 2007;115:29-35.

62. Cristol LS, Jialal I, Grundy SM. Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. Atherosclerosis. 1992;97:11-20.

63. Kaminnyi AI, Lankin VZ, Perepelitsa EI, et al. Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients. Bull Exp Biol Med. 2007;144:664-6.

64. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA. 1987;84:7725-9.

65. Kita T, Yokode M, Ishii K, et al. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol Suppl. 1992;20:37-42.

66. Guo YS, Wang CX, Cao J, et al. Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome. J Thorac Dis. 2015;7:368-75.

67. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151-5.

68. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis. 2003;171:131-6.

69. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2006;47:77-81.

70. Inagaki M, Nakagawa-Toyama Y, Nishida M, et al. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2012;19:643-56.

71. Yao S, Tian H, Zhao L, et al. Oxidized high density lipoprotein induces macrophage apoptosis via toll-like receptor 4-dependent CHOP pathway. J Lipid Res. 2017;58:164-77.

72. Okada T, Sumida M, Ohama T, et al. Development and clinical application of an enzyme-linked immunosorbent assay for oxidized high-density lipoprotein. J Atheroscler Thromb. 2021;28:703-15.

73. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987;84:5928-31.

74. Niimi M, Keyamura Y, Nozako M, et al. Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Lipids Health Dis. 2013;12:166.

75. Li S, Liang J, Niimi M, et al. Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. J Atheroscler Thromb. 2014;21:648-58.

76. Chen C, Wang Y, Cao Y, et al. Mechanisms underlying the inhibitory effects of probucol on elastase-induced abdominal aortic aneurysm in mice. Br J Pharmacol. 2020;177:204-16.

77. Li Y, Zhao Q, Cao Y, et al. Probucol decreases homocysteine-stimulated CRP production in rat aortic smooth muscle cells via regulating HO-1/NADPH oxidase/ROS/p38 pathway. Acta Biochim Biophys Sin. 2021;53:212-9.

78. Ko YG, Choi SH, Chol Kang W, Kwon Lee B, Wook Kim S, Shim WH. Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial. J Atheroscler Thromb. 2014;21:816-30.

79. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39:610-6.

80. Yamashita S, Bujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008;15:292-303.

81. Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis. 2012;220:463-9.

82. Yamashita S, Masuda D, Ohama T, et al. Rationale and design of the PROSPECTIVE trial: probucol trial for secondary prevention of atherosclerotic events in patients with prior coronary heart disease. J Atheroscler Thromb. 2016;23:746-56.

83. Yamashita S, Arai H, Bujo H, et al. Probucol trial for secondary prevention of atherosclerotic events in patients with coronary heart disease (PROSPECTIVE). J Atheroscler Thromb. 2021;28:103-23.

84. Kang HJ, Kim MH, Sung J, et al. Effect of probucol and/or cilostazol on carotid intima media thickness in patients with coronary heart disease: a randomized, multicenter, multinational study. J Atheroscler Thromb. 2021;28:124-36.

85. Arai H, Bujo H, Masuda D, et al. Integrated analysis of two probucol trials for the secondary prevention of atherosclerotic cardiovascular events: PROSPECTIVE and IMPACT. J Atheroscler Thromb. 2022;29:850-65.

86. Hong KS, Kim BJ, Lee JY, Kwon SU; PICASSO Investigators. Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: a randomized controlled trial. Int J Stroke. 2015;10:1153-8.

87. Kim BJ, Lee EJ, Kwon SU, et al. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurol. 2018;17:509-18.

88. Seo WK, Kim YJ, Lee J, Kwon SU; PICASSO Investigators. Design and rationale of the intima-medial thickness sub-study of the prevention of CArdiovascular events in iSchemic stroke patients with high risk of cerebral hemOrrhage (PICASSO-IMT) study. J Stroke Cerebrovasc Dis. 2017;26:1892-8.

89. Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther. 1993;15:374-382.

90. Tardif JC, Cöté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997;337:365-72.

91. Côté G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation. 1999;99:30-5.

92. Daida H, Kuwabara Y, Yokoi H, et al. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol. 2000;86:550-2, A9.

93. Liu J, Li M, Lu H, et al. Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One. 2015;10:e0124021.

94. Harada Y, Colleran R, Kufner S, et al. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Cardiovasc Diabetol. 2016;15:124.

95. Kufner S, Sorges J, Mehilli J, et al. Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial. JACC Cardiovasc Interv. 2016;9:784-92.

96. Zuhdi AS, Krackhardt F, Waliszewski MW, Ismail MD, Boxberger M, Wan Ahmad WA. Efficacy and safety of polymer-free ultrathin strut sirolimus-probucol coated drug-eluting stents for chronic total occlusions: insights from the coroflex ISAR 2000 worldwide registry. Cardiol Res Pract. 2018;2018:8053168.

97. Chen KQ, Ke BY, Cheng L, Guan MT, Wang ZB, Wang SZ. Research and progress of probucol in nonalcoholic fatty liver disease. Mini Rev Med Chem. 2023;23:1905-11.

98. Cui X, Xie B, Wang H, et al. Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2023;102:e33273.

99. Navarese EP, Gurbel PA, Andreotti F, et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One. 2017;12:e0168726.

100. Pranata R, Yonas E, Vania R, Lukito AA. The role of probucol preventing contrast-induced nephropathy in patients undergoing invasive coronary procedures - Systematic review and meta-analysis of randomized controlled trials. Turk Kardiyol Dern Ars. 2021;49:51-9.

101. Sharif A, Mamo J, Lam V, et al. The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases. Transl Neurodegener. 2024;13:6.

102. Liao J, Bai J, An X, et al. Lipoprotein glomerulopathy-like lesions in atherosclerotic mice defected with HDL receptor SR-B1. Front Cardiovasc Med. 2021;8:734824.

103. Liang X, Li H, Li X, et al. Highly sensitive H₂O₂-scavenging nano-bionic system for precise treatment of atherosclerosis. Acta Pharm Sin B. 2023;13:372-89.

104. Chen F, Chen J, Han C, et al. Theranostics of atherosclerosis by the indole molecule-templated self-assembly of probucol nanoparticles. J Mater Chem B. 2021;9:4134-42.

105. Zeng J, Zhang Y, Gao Y, et al. Biomimetic ginsenoside Rb1 and probucol Co-assembled nanoparticles for targeted atherosclerosis therapy via inhibition of oxidative stress, inflammation, and lipid deposition. ACS Nano. 2025;19:22968-87.

106. Fu X, Yu X, Jiang J, et al. Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis. Nat Commun. 2022;13:6528.

107. Chen L, Yang J, Fu X, et al. A targeting mesoporous dopamine nanodrug platform with NIR responsiveness for atherosclerosis improvement. Biomater Adv. 2022;136:212775.

108. Liang X, Li H, Zhang A, et al. Red blood cell biomimetic nanoparticle with anti-inflammatory, anti-oxidative and hypolipidemia effect ameliorated atherosclerosis therapy. Nanomedicine. 2022;41:102519.

109. Wagle SR, Kovacevic B, Ionescu CM, et al. Pharmacological and biological study of microencapsulated probucol-secondary bile acid in a diseased mouse model. Pharmaceutics. 2021;13:1223.

110. Wu Z, Wang X, Jiang X. Study on the mechanism of probucol nanosuspension on hyperlipidemic pancreatitis and regulation of blood lipid function. J Nanosci Nanotechnol. 2021;21:1286-92.

111. Wagle SR, Kovacevic B, Ionescu CM, et al. Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an in vitro study. Ther Deliv. 2024;15:237-52.

112. Okamura T, Tsukamoto K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2024;31:641-853.

113. Japan Atherosclerosis Society. Guide for Management of Dyslipidemia for Prevention of Atherosclerotic Cardiovascular Diseases. 2023 Edition (in Japanese).